Arcus Biosciences (RCUS) FY2022 results: revenue $112 million, down 70.7% on the year
Arcus Biosciences, Inc. (RCUS) reported revenue of $112 million for fiscal 2022, the year ended 31 December 2022, down 70.7% on the year before. Net income was -$267 million, and diluted earnings per share $-3.71. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2025.
Revenue
$112 million
-70.7% on the year
FY2017FY2022
Operating margin
-250.0%
14.1% a year earlier
FY2017FY2022
Net income
-$267 million
FY2017FY2022
Diluted EPS
-$3.71
FY2017FY2022
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Operating cash flow
438
-256
111
Capital expenditure
6.0
26.0
3.0
-76.9%
Free cash flow
432
-282
108
Free cash flow margin
385.7%
-73.7%
138.7%
Cash from investing
-413
-4.0
-434
Cash from financing
33.0
237
439
-86.1%
Depreciation and amortisation
6.0
4.0
3.0
+50.0%
Share-based compensation
65.0
55.0
22.0
+18.2%
Diluted shares, weighted
72m
74m
55m
-2.7%
Shares outstanding at period end
73m
71m
65m
+3.0%
Balance sheet
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Shareholders' equity
657
841
502
-21.9%
Debt
0.0
0.0
0.0
Operating lease liabilities
117
117
15.2
+0.1%
Other liabilities
571
634
255
-9.9%
Total liabilities and equity
1,345
1,592
772
-15.5%
Fixed assets
35.0
32.0
10.8
+9.4%
Investments
932
533
562
+74.7%
Cash and equivalents
206
148
173
+39.3%
Other assets
172
879
26.4
-80.4%
Total assets
1,345
1,592
772
-15.5%
10-K for the year ended 31 December 2022, filed 25 February 2025: the filing.